ADRB2 and cancer: These angiogenic effects were observed to be inducible with use of salmeterol (an ADRβ2 agonist) and reversible with the use of propranolol (a nonselective β-adrenergic antagonist) [15], suggesting that in certain cancer types, antiadrenergic treatment may show promise in slowing cancer progression either as monotherapy or in combination with anti-VEGF agents.